Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment
Naderi, Nazanin LU
(2020)
In Clinical and Experimental Rheumatology
38(2, Suppl 124).
- Abstract
- Giant cell arteritis (GCA), a systemic large-vessel vasculitis, is a disease that has been treated with glucocorticoids since 1950. Over the years, several disease-
modifying anti-rheumatic drugs have been evaluated as steroid-sparing agents with disappointing results. Tocilizumab, an interleukin-6 inhibitor, has in recent years been approved for the treatment of GCA. It remains uncertain whether the drug suppresses disease activity and maintains remission or just alleviates the symptoms and masks the signs of smoldering disease. This case describes the clinical findings at diagnosis and the course of the disease with the subsequent development of intracranial vasculitis in a 70-year-old male treated with tocilizumab. The present case... (More) - Giant cell arteritis (GCA), a systemic large-vessel vasculitis, is a disease that has been treated with glucocorticoids since 1950. Over the years, several disease-
modifying anti-rheumatic drugs have been evaluated as steroid-sparing agents with disappointing results. Tocilizumab, an interleukin-6 inhibitor, has in recent years been approved for the treatment of GCA. It remains uncertain whether the drug suppresses disease activity and maintains remission or just alleviates the symptoms and masks the signs of smoldering disease. This case describes the clinical findings at diagnosis and the course of the disease with the subsequent development of intracranial vasculitis in a 70-year-old male treated with tocilizumab. The present case illustrates the need for further studies regarding tocilizumab
in the treatment of GCA patients
and the need for meticulous evaluation
at follow-ups. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/58d33a36-40c6-47fc-8776-132221ba0d03
- author
- Naderi, Nazanin
LU
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- giant cell arteritis, intracranial vasculitis, biological therapy, tocilizumab, blood pressure, arterial pressure
- in
- Clinical and Experimental Rheumatology
- volume
- 38
- issue
- 2, Suppl 124
- article number
- CER13254
- publisher
- Pacini
- external identifiers
-
- pmid:32359040
- scopus:85085537978
- ISSN
- 1593-098X
- language
- English
- LU publication?
- no
- id
- 58d33a36-40c6-47fc-8776-132221ba0d03
- date added to LUP
- 2020-05-05 21:03:55
- date last changed
- 2024-02-10 04:06:19
@article{58d33a36-40c6-47fc-8776-132221ba0d03,
abstract = {{Giant cell arteritis (GCA), a systemic large-vessel vasculitis, is a disease that has been treated with glucocorticoids since 1950. Over the years, several disease-<br/>modifying anti-rheumatic drugs have been evaluated as steroid-sparing agents with disappointing results. Tocilizumab, an interleukin-6 inhibitor, has in recent years been approved for the treatment of GCA. It remains uncertain whether the drug suppresses disease activity and maintains remission or just alleviates the symptoms and masks the signs of smoldering disease. This case describes the clinical findings at diagnosis and the course of the disease with the subsequent development of intracranial vasculitis in a 70-year-old male treated with tocilizumab. The present case illustrates the need for further studies regarding tocilizumab<br/>in the treatment of GCA patients<br/>and the need for meticulous evaluation<br/>at follow-ups.}},
author = {{Naderi, Nazanin}},
issn = {{1593-098X}},
keywords = {{giant cell arteritis; intracranial vasculitis; biological therapy; tocilizumab; blood pressure; arterial pressure}},
language = {{eng}},
number = {{2, Suppl 124}},
publisher = {{Pacini}},
series = {{Clinical and Experimental Rheumatology}},
title = {{Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment}},
volume = {{38}},
year = {{2020}},
}